Davis's Drug Guide
lisocabtagene maraleucel
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
lis-oh-kab-ta-jeen mar-a-loo-sel
Trade Name(s)
- Breyanzi
Ther. Class.
Pharm. Class.
CAR-T cell immunotherapies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Lisocabtagene Maraleucel." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Harriet Lane, www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580210/10/lisocabtagene_maraleucel.
Vallerand AHA, Sanoski CAC. Lisocabtagene maraleucel. Davis's Drug Guide. F.A. Davis Company; 2026. https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580210/10/lisocabtagene_maraleucel. Accessed October 23, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Lisocabtagene maraleucel. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580210/10/lisocabtagene_maraleucel
Vallerand AHA, Sanoski CAC. Lisocabtagene Maraleucel [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 October 23]. Available from: https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580210/10/lisocabtagene_maraleucel.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - lisocabtagene maraleucel
ID - 3580210
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://www.unboundmedicine.com/harrietlane/view/Davis-Drug-Guide/3580210/10/lisocabtagene_maraleucel
PB - F.A. Davis Company
ET - 20
DB - Harriet Lane
DP - Unbound Medicine
ER -
